The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (CSCC).
 
Danny Rischin
Research Funding - Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Merck; Regeneron
Travel, Accommodations, Expenses - Merck
 
Matthew G. Fury
Employment - Regeneron; Regeneron (I)
Stock and Other Ownership Interests - Regeneron; Regeneron (I)
Research Funding - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneorn; Regeneron (I)
 
Israel Lowy
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneron
 
Elizabeth Stankevich
Employment - Regeneron
Stock and Other Ownership Interests - Bristol-Myers Squibb; Merck; Regeneron
 
Hyunsil Han
Employment - Regeneron
Stock and Other Ownership Interests - Regeneron
Research Funding - Regeneron
Travel, Accommodations, Expenses - Regeneron
 
Sandro Porceddu
Consulting or Advisory Role - Merck Serono; Merck Sharp & Dohme; Oral Oncology; UpToDate
Travel, Accommodations, Expenses - Merck Serono; Merck Sharp & Dohme